Hepatitis C News and Research

Latest Hepatitis C News and Research

EC approves Janssen’s DACOGEN for treatment of de novo acute myeloid leukaemia

Janssen-Cilag International NV announced today that the European Commission has approved the marketing authorisation for DACOGEN(decitabine) for the treatment of adult patients (age 65 years and above) with newly diagnosed de novo or secondary acute myeloid leukaemia (AML), according to the World Health Organisation (WHO) classification, who are not candidates for standard induction chemotherapy.

28 Sep 2012

Thymus tissue, iPSCS and liver cells can thrive in lymph nodes

Lymph nodes can provide a suitable home for a variety of cells and tissues from other organs, suggesting that a cell-based alternative to whole organ transplantation might one day be feasible, according to researchers at the University of Pittsburgh School of Medicine and its McGowan Institute for Regenerative Medicine.

28 Sep 2012

Incarcerated patients with chronic HCV likely to achieve sustained viral response

Incarcerated patients with chronic hepatitis C virus (HCV) infection are just as likely to respond to treatment for the disease as patients in the community, according to findings published in the October issue of Hepatology, a peer-reviewed journal of the American Association for the Study of Liver Diseases.

28 Sep 2012

InterCure signs strategic service agreement with private company

XTL Biopharmaceuticals Ltd. today announced that InterCure Ltd., which is approximately 45.4% (50.79% on a fully diluted basis) held by XTL, signed a strategic service agreement with a private company wholly owned by Mr. Shay Ben Yitzhak and Mr. Avner Yassur.

25 Sep 2012

PPI use linked with risk for infection in decompensated cirrhosis

Proton-pump inhibitors are associated with an increased risk for serious infections in patients with decompensated cirrhosis, research shows.

24 Sep 2012

NanoViricides’ oral FluCide dramatically improves survival in animals with H3N2 influenza A

NanoViricides, Inc. reported today that its oral FluCide drug candidates demonstrated dramatically improved survival in animals administered a lethal dose of the H3N2 influenza A virus.

24 Sep 2012

State roundup: Big changes ahead for Mich. Blue Cross; End-of-life planning programs spreading; Texas mental health treatment shortage

The Michigan Legislature took its first steps Wednesday toward tackling a proposed overhaul of the state's largest health insurer, Blue Cross Blue Shield of Michigan. Senate Insurance Committee Chairman Joe Hune introduced bills that would end the nonprofit health insurer's tax-exempt status and align it with competitors.

21 Sep 2012

Medivir’s simeprevir and TMC647055 to enter phase IIa combination trial for HCV genotype-1

Medivir AB, announced today that simeprevir (TMC435) and TMC647055, a non-nucleoside inhibitor (NNI) will enter a phase IIa interferon free combination trial.

21 Sep 2012

Positive data from Nektar’s NKTR-192 Phase 1a study on acute pain

Nektar Therapeutics announced today that positive data from the first single-ascending dose Phase 1a clinical study of NKTR-192, the company's novel short-acting mu-opioid analgesic candidate, demonstrate that the drug candidate achieved its target pharmacokinetic profile.

19 Sep 2012

Orthopedists should suspect necrotizing fasciitis in patients with out of proportion pain

Dr. Russell Russo, an Orthopedic Surgeon at LSU Health Sciences Center New Orleans, and other researchers stress that orthopedists should have a high index of suspicion for necrotizing fasciitis, or flesh-eating bacterial infection, in every patient with pain or other symptoms that are out of proportion to the initial diagnosis. Their recommendations are published in the September 2012 issue of Orthopedics Today.

17 Sep 2012

New test to assess viral load of cytomegalovirus

Roche announced today the commercial availability of a new test to assess a patient's viral load of cytomegalovirus (CMV). Physicians use information from the test to help them manage patients who have been diagnosed with CMV disease, specifically patients with an immune system that has been suppressed for solid organ transplantation.

From Roche Sequencing and Life Science 17 Sep 2012

Drinking water fails to meet state quality standards at North Carolina migrant farmworker camps

The drinking water at one-third of migrant farmworker camps in eastern North Carolina failed to meet state quality standards, according to a new study from Wake Forest Baptist Medical Center.

15 Sep 2012

First demonstration of newly developed dual humanized FRGTM KO system against malaria

A novel human liver-chimeric mouse model developed at Oregon Health & Science University and Yecuris Corporation has made possible a research breakthrough at Seattle Biomedical Research Institute that will greatly accelerate studies of the most lethal forms of human malaria.

11 Sep 2012

Warning over sirolimus in HCV-positive liver transplantation

Sirolimus, whether given at the time of liver transplantation or after, is associated with poorer outcomes in patients with hepatitis C virus infection compared with those who do not take the immunosuppressant, shows a US study.

10 Sep 2012

GSK, University of Cambridge aim to discover and develop new medicines for liver disease

A new collaboration based at the University of Cambridge will aim to discover and develop new medicines to treat liver disease.

10 Sep 2012

Children and young patients with chronic HBV infection do have a protective immune response

Scientists from A*STAR's Singapore Institute for Clinical Sciences (SICS), together with clinical collaborators from London , discovered for the first time that children and young patients with chronic Hepatitis B Virus infection (HBV carriers) do have a protective immune response, contrary to current belief, and hence can be more suitable treatment candidates than previously considered.

7 Sep 2012

Study finds excellent outcomes for patients with acute liver failure after LDLT

Patients in Japan who underwent living donor liver transplantation (LDLT) for acute liver failure (ALF) were classified as having excellent outcomes, with ten-year survival at 73%.

7 Sep 2012

University of Rhode Island engineers develop new blood-testing technology

A team of engineers and students at the University of Rhode Island has developed an advanced blood-testing technology that incorporates a smartphone application, a hand-held biosensor and a credit card-sized cartridge to provide rapid, accurate biological analysis and wireless communication of test results.

7 Sep 2012

New findings establish connection between microRNAs and cellular metabolism

New findings establish a connection between microRNAs and cellular metabolism, suggesting that a drug designed to inhibit these tiny molecules -- once considered to be "junk" DNA -- would have a positive effect against obesity.

7 Sep 2012

Longer looks: Insurers balk at price of new asthma relief; Despite health law, costs still overwhelming for some patients

For two decades, Patricia DiGiusto struggled with severe asthma. Powerful medications and frequent use of her inhaler could not prevent repeated trips to the emergency room. ... Two years ago, Ms. DiGiusto's doctor told her about a new procedure called bronchial thermoplasty, the first non-drug therapy approved by the Food and Drug Administration for patients with severe asthma.

7 Sep 2012

Hepatitis C News and Research

Latest Hepatitis C News and Research

EC approves Janssen’s DACOGEN for treatment of de novo acute myeloid leukaemia

Thymus tissue, iPSCS and liver cells can thrive in lymph nodes

Incarcerated patients with chronic HCV likely to achieve sustained viral response

InterCure signs strategic service agreement with private company

PPI use linked with risk for infection in decompensated cirrhosis

NanoViricides’ oral FluCide dramatically improves survival in animals with H3N2 influenza A

State roundup: Big changes ahead for Mich. Blue Cross; End-of-life planning programs spreading; Texas mental health treatment shortage

Medivir’s simeprevir and TMC647055 to enter phase IIa combination trial for HCV genotype-1

Positive data from Nektar’s NKTR-192 Phase 1a study on acute pain

Orthopedists should suspect necrotizing fasciitis in patients with out of proportion pain

New test to assess viral load of cytomegalovirus

Drinking water fails to meet state quality standards at North Carolina migrant farmworker camps

First demonstration of newly developed dual humanized FRGTM KO system against malaria

Warning over sirolimus in HCV-positive liver transplantation

GSK, University of Cambridge aim to discover and develop new medicines for liver disease

Children and young patients with chronic HBV infection do have a protective immune response

Study finds excellent outcomes for patients with acute liver failure after LDLT

University of Rhode Island engineers develop new blood-testing technology

New findings establish connection between microRNAs and cellular metabolism

Longer looks: Insurers balk at price of new asthma relief; Despite health law, costs still overwhelming for some patients

Unlocking live single-cell functional insights

Fluidics in Modern Healthcare & Medical Device Innovation

How microRNA is transforming science: From discovery to diagnostics

Hepatitis C News and Research

Latest Hepatitis C News and Research

Unlocking live single-cell functional insights

Fluidics in Modern Healthcare & Medical Device Innovation

How microRNA is transforming science: From discovery to diagnostics

Newsletters you may be interested in